RT Journal Article
SR Electronic
T1 Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 75
OP 80
DO 10.21873/anticanres.13927
VO 40
IS 1
A1 TAKASHI KIJIMA
A1 TAKAAKI ARIGAMI
A1 YOSHIKAZU UENOSONO
A1 TSUBASA HIRAKI
A1 SHIGEHIRO YANAGITA
A1 DAISUKE MATSUSHITA
A1 KEISHI OKUBO
A1 MASATAKA SHIMONOSONO
A1 SUMIYA ISHIGAMI
A1 KOSEI MAEMURA
A1 AKIHIDE TANIMOTO
A1 SHOJI NATSUGOE
YR 2020
UL http://ar.iiarjournals.org/content/40/1/75.abstract
AB Background/Aim: The aim of the present study was to compare human epidermal growth factor receptor 2 (HER2) expression before and after trastuzumab-based chemotherapy in patients with advanced HER2-positive gastric cancer. Materials and Methods: We assessed HER2 expression using immunohistochemistry and/or fluorescence in situ hybridization in pre-treatment biopsied specimens and post-treatment resected specimens obtained from seven patients with advanced HER2-positive gastric cancer receiving trastuzumab-based chemotherapy. Results: Four patients maintained the HER2-positive status and three patients had a change in HER2 expression from positive to negative. In patients showing the loss of HER2 expression after treatments, HER2-positive tumor cells with a dominant histological type disappeared, and HER2-negative tumor cells with another dominant histological type were identified. Conclusion: HER2 expression can change after trastuzumab-based chemotherapy in patients with advanced HER2-positive gastric cancer. Continuous monitoring of HER2 expression after treatments may be utilized to determine whether the continued use of trastuzumab is advisable.